🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Timely tour de force review on Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches | Journal of Clinical Oncology Toby Eyre ascopubs.org/doi/full/10.12…

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

🚨🚨Paper out! 🚨🚨 Delighted to share our work, now published in Nature Genetics 🧬! shorturl.at/94s5S We identified a targetable, chromothripsis-associated genetic event in blast phase (BP) MPN, a particularly poor prognostic subtype of acute leukaemia. 1/n 🧵👇

#Hematology Clonal relatedness as a prognostic marker in #Richter transformation of chronic lymphocytic leukemia #CLL: a systematic review | ⁦Blood Advances⁩ #CLLsm #lymsm #leusm ashpublications.org/bloodadvances/…

CLL13 longer follow up - huge study and great presentation. Though GIV is superior, I would not use as SOC since the duration of therapy is longer (range 12-36 months) than ven/obi which is still quite excellent (and always 1 yr). And yes MRD still matters! #EHA25 #EHA2025

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment ashpublications.org/blood/article-…

Presented at #EHA2025: Among patients with chronic lymphocytic leukemia, undetectable MRD and progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone or chemoimmunotherapy, with benefits sustained at 5 years. Full FLAIR phase 3 trial

➡️➡️Big CLL news! Munir et al OS and PFS adv for MRD driven I&V over ibrutinib in 1L #CLL #EHA2025 Congrats to all FLAIR trial 🇬🇧group Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia | New England Journal of Medicine nejm.org/doi/full/10.10…

Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826 | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Toby Eyre on treatment options in R/R MCL exposed in 1L to BtKi. Time limites exposure to BTKi allows for reexposure at 1st relapse (+/- venetoclax) #18icml #icml2025

Only 2 years until Lugano 2027! #ICML2027

ICML25: Outpatient fixed duration Mosun-Pola regimen is highly efficacious in 3L+ R/R MCL in this phase 2 cohort: 71% had 3+ high risk features (prior CAR, ASCT, TP53, Blastoid/pleomorphic, Ki67 30%+ etc). ORR 88%, CR79% CRS all low grade and resolved.

The disease shift of chronic lymphocytic leukemia to diffuse large B-cell lymphoma, so-called Richter transformation, is a catastrophic clinical event. ow.ly/XT0K50W7sNp #lymphoidneoplasia

Important potential pivotal ongoing RCT in R/R #MCL BGB‐11417‐302, A PHASE 3, RANDOMIZED, DOUBLE‐BLIND STUDY OF SONROTOCLAX (BGB‐11417) + ZANUBRUTINIB VERSUS PLACEBO + ZANUBRUTINIB IN R/R MCL - Hematological Oncology onlinelibrary.wiley.com/doi/full/10.10…

Zanubrutinib approved for relapsed #MCL by NICE #lymsm Final draft guidance avaliable nice.org.uk/guidance/indev…

Happy to share the French experience of CAR-T cells therapy for patients with #RichterTransformation ! Check our last paper. onlinelibrary.wiley.com/doi/10.1111/bj… Lysa Lymphoma @CHUClermontFd

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

We’re bringing the UK's leading lymphoma experts straight to your screen for #LymphomaManagement 2025. Are you a registrar, consultant, specialist nurse, pharmacist or other healthcare professional? Register now 👉 lymphoma-action.org.uk/events/lymphom… #LymSM #Lymphoma Toby Eyre Graham Collins

Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia sciencedirect.com/science/articl…